Petmed Express earnings release, August 13, 2026

Petmed Express Inc (PETS) · Form 8-K, Item 2.02 · Filed · SEC filing

PetMeds® Announces First Quarter Financial Results

Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026.

Quarterly Highlights

• Net sales demonstrated sequential quarterly stabilization. For the first quarter ended June 30, 2026, net sales were $41.0 million compared to $51.2 million for the prior year period, a decrease of 19.9%, as lower consumer promotional usage was more than offset by a decline in prescription medication sales.

• Net loss for the quarter ended June 30, 2026, was $6.1 million, or $(0.28) per diluted share, compared to a net loss of $34.2 million, or $(1.65) per diluted share, for the prior year period. The decrease in net loss was primarily driven by the absence of the prior-year goodwill and trade name impairment charges and to a lesser extent lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.

• Adjusted EBITDA¹ was $(3.4) million compared to $(2.7) million in the prior year period.

“Our first quarter results reflect continued progress toward our goal of establishing a direct, clear path back to sustainable profitability," said Leslie Campbell, Chairman and Interim CEO and President of PetMeds. "We are pleased that net sales have stabilized sequentially over the past several quarters, and we continued to make our marketing spend more efficient, acquiring 70,000 new customers while reducing our cost of acquiring a new customer by 15% year-over-year. At the same time, disciplined expense management drove a nearly 14% reduction in general and administrative expenses. We also completed one of the largest milestones in our technology transformation with the enterprise-wide rollout of our new SAP ERP system, further modernizing and strengthening our financial systems and reporting processes. And with our recently announced sale-leaseback transaction, we took an important step toward strengthening our balance sheet and enhancing our financial flexibility to invest in the initiatives with the greatest potential to drive shareholder returns."

Earnings Webcast

A webcast reviewing financial results for the first quarter fiscal year ended June 30, 2026 is available at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com

Forward Looking Statement

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except for share and per share amounts) (Unaudited)

Three Months Ended June 30, – 20262025
Net sales41,01551,180
Cost of sales29,68236,777
Gross profit11,33314,403
Operating expenses:General and administrative11,19712,948
Operating expenses:Advertising4,2206,046
Operating expenses:Depreciation and amortization2,1482,283
Operating expenses:Impairment of goodwill and intangible assets27,258
Operating expenses:Total operating expenses17,56548,535
Operating expenses:Loss from operations-6,232-34,132
Other income:Interest (expense) income, net-338-198
Other income:Other, net438187
Other income:Total other income (expense)100-11
Other income:Loss before provision for income taxes-6,132-34,143
Other income:Provision for income taxes139
Other income:Net loss-6,145-34,152
Other income:Basic and diluted net loss per share-0.28-1.65
Other income:Basic and diluted weighted-average common shares outstanding21,682,38120,755,416

Income Statement

Three Months Ended — PetMed Express, Inc. ($ in thousands, except percentages)

Three Months Ended – June 30, 2026 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Three Months Ended – June 30, 2025 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:$ Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:% Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss-6,145-34,15228,00782.0%
Add (subtract):Stock-based Compensation198591-393-66.0%
Add (subtract):Income Taxes139444.0%
Add (subtract):Depreciation and Amortization2,1482,283-135-6.0%
Add (subtract):Interest Expense (Income), Net33819814071.0%
Add (subtract):Employee Severance95-95n/m
Add (subtract):Professional Fees (1)1,021-1,021n/m
Add (subtract):Impairment of goodwill and intangible assets27,258-27,258n/m
Add (subtract):Adjusted EBITDA-3,448-2,697-75128.0%

Balance Sheet

(In thousands, except for share and per share amounts) (Unaudited)

June 30, 2026 – (Unaudited)March 31, 2026
Current assets:Cash and cash equivalents13,07921,412
Current assets:Accounts receivable, less allowance for credit losses of $0 and $25, respectively1,7061,908
Current assets:Inventories, net8,46813,608
Current assets:Prepaid expenses and other current assets4,2566,378
Current assets:Prepaid income taxes96258
Current assets:Total current assets27,60543,564
Noncurrent assets:Property and equipment, net25,21326,326
Noncurrent assets:Intangible and other assets, net10,54910,789
Noncurrent assets:Operating lease right-of-use assets, net395512
Noncurrent assets:Total noncurrent assets36,15737,627
Noncurrent assets:Total assets63,76281,191
Current liabilities:Accounts payable12,29820,906
Current liabilities:Sales tax payable20,60322,261
Current liabilities:Accrued expenses and other current liabilities6,6547,665
Current liabilities:Current operating lease liabilities414493
Current liabilities:Deferred revenue629689
Current liabilities:Income taxes payable20
Current liabilities:Total current liabilities40,59852,034
Current liabilities:Deferred tax liabilities, net175175
Current liabilities:Operating lease liabilities, net of current lease liabilities42
Current liabilities:Total liabilities40,77352,251
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Convertible preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively99
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Common stock, $.001 par value, 40,000,000 shares authorized; 21,682,381 and 21,385,638 shares issued and outstanding, respectively2221
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Additional paid-in capital19,84019,647
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Retained earnings3,1189,263
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Total shareholders' equity22,98928,940
Preferred stock, $0.001 par value, 5,000,000 shares authorized:Total liabilities and shareholders' equity63,76281,191

Cash Flow

Three Months Ended June 30, — (In thousands) (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-6,145-34,152
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization2,1482,283
Adjustments to reconcile net loss to net cash used in operating activities:Impairment of goodwill and intangible assets27,258
Adjustments to reconcile net loss to net cash used in operating activities:Share based compensation198591
Adjustments to reconcile net loss to net cash used in operating activities:Bad debt (recovery) expense-6
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:Accounts receivable202718
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:Inventories5,140-2,156
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:Prepaid income taxes162
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:Prepaid expenses and other current assets2,122-1,170
Full release

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K to be filed for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements,¹

Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures. which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact:

ICR, LLC

Reed Anderson

(646) 277-1260 investor@petmeds.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Petmed Express earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.